# US 2023/0067960 A1 · Triple agonist for glucagon-like peptide-1 receptor, glucagon receptor, and gastric inhibitory polypeptide receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0067960 A1
- Document ID: US20230067960A1
- Status: Published application
- Kind: A1
- Application number: 17/788,738
- Filed: 2021-02-07
- Published: 2023-03-02
- Earliest claimed: 2019-12-23
- Assignees: Vonsun Pharmatech Co., Ltd.
- Applicants: Vonsun Pharmatech Co., Ltd.
- Inventors: Zhongshuai XIN; Yifei LI; Liangzhu WEN; Yuanguang ZHONG; Huimei CHEN; Mingyi ZHANG; Mei ZHAO
- Web page: https://patentgrep.com/patent/US20230067960A1

## CPC

- C07K 14/605: Glucagons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided is a triple agonist for the glucagon-like peptide-1 receptor (GLP1-R), glucagon receptor (GCGR), and gastric inhibitory polypeptide receptor (GIPR), the triple agonist being based on the amino acid sequence of natural exendin-4 with at least one site having an amino acid substitution, mutation, or chemical modification. The triple agonist of the present invention can be used for the prevention or treatment of metabolic syndrome.

## Claims

### Claim 1

A triple agonist of glucagon-like peptide-1 receptor (GLP1-R), glucagon receptor (GCGR) and gastric inhibitory peptide receptor (GIPR), comprising a peptide having an amino acid sequence of general formula 1:
His-Xaa1-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Xaa2-Xaa3-Xaa4-Glu-Xaa5-Xaa6-Ala-Xaa7-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Xaa8-Xaa9-Gly-Gly-Pro-Ser- Ser-Gly-Ala-Pro -Pro-Pro-Xaa10
wherein, in general formula 1:
Xaa1 is selected from the group consisting of glycine (Gly, G) and aminoisobutyric acid (Aib);
Xaa2 is selected from the group consisting of alanine (Ala, A), arginine (Arg, R) and leucine (Leu, L);
Xaa3 is selected from the group consisting of alanine (Ala, A), glutamic acid (Glu, E) and tyrosine (Tyr, Y);
Xaa4 is selected from the group consisting of methionine (Met, M), leucine (Leu, L) and glutamine (Gln, Q);
Xaa5 is selected from the group consisting of lysine (Lys, K), K-R1 and K-R2, wherein the side chain of K-R1 and K-R2 are chemically modified with lipophilic group;
Xaa6 is selected from the group consisting of glutamic acid (Glu, E) and isoleucine (Ile, I);
Xaa7 is selected from the group consisting of alanine (Ala, A) and valine (Val, V);
Xaa8 is selected from the group consisting of isoleucine (Ile, I) and arginine (Arg, R);
Xaa9 is selected from the group consisting of aspartic acid (Asp, D) and glutamic acid (Glu, E); and
Xaa10 is selected from the group consisting of serine (Ser, S) and amidated serine (S-NH2).

### Claim 2 (depends on 1)

The triple agonist according to claim 1, wherein K-R1 has a chemical structure of:
and K-R2 has a chemical structure of:

### Claim 3 (depends on 1, 2)

The triple agonist according to claim 1, wherein the amino acid sequence is selected from the group consisting of SEQ ID NOs. 1-14 in the following table:
SEQ
ID
NO.
Amino acid sequence
l
HXQGT FTSDL SRAME KIAVR LFIEW LREGG PSSGA PPPS
2
HXQGT FTSDL SRAME KEAVR LFIEW LREGG PSSGA PPPS
3
HXQGT FTSDL SRAME KEAVR LFIEW LIEGG PSSGA PPPS
4
HXQGT FTSDL SRAME KEAVR LFIEW LIDGG PSSGA PPPS
5
HXQGT FTSDL SAAME KIAVR LFIEW LREGG PSSGA PPPS
6
HXQGT FTSDL SRAME KIAVR LFIEW LIEGG PSSGA PPPS
7
HXQGT FTSDL SRALE KIAAR LFIEW LIEGG PSSGA PPPS
8
HXQGT FTSDL SLAQE KEAVR LFIEW LREGG PSSGA PPPS
9
HXQGT FTSDL SLEQE KIAVR LFIEW LREGG PSSGA PPPS
10
HXQGT FTSDL SRYLE KEAVR LFIEW LIDGG PSSGA PPPS
11
12
13
14
wherein, K-R1 and K-R2 are as defined in claim 2.

### Claim 4 (depends on 1)

A polynucleotide encoding the triple agonist according to claim 1.

### Claim 5 (depends on 1)

A recombinant expression vector or transformant comprising the triple agonist according to claim 1.

### Claim 6 (depends on 1)

A composition comprising the triple agonist according to claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 7 (depends on 1)

A method for treating or preventing metabolic syndrome, comprising administering the triple agonist according to claim 1, to a subject in need thereof.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the metabolic syndrome is diabetes mellitus, obesity, hypertension, dyslipidemia, hypercholesterolemia, non-alcoholic steatohepatitis, or arteriosclerosis and coronary heart disease caused by hypercholesterolemia and hyperlipidemia.
